Latest Videos
Biomarker Consortium Videos
Dr Schneider on Diagnostic Testing Turnaround Times in Lung Cancer
Dr Schneider on Diagnostic Testing Turnaround Times in Lung Cancer
Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations
Dr Rodriguez on Treating Patients With Lung Cancer Harboring Multiple Actionable Mutations
Dr Olazagasti on the Use of Biomarker Testing in Lung Cancer
Dr Olazagasti on the Use of Biomarker Testing in Lung Cancer
Dr Kim on NSCLC Treatment Selection Based on Biomarker Testing Results
Dr Kim on NSCLC Treatment Selection Based on Biomarker Testing Results
Dr Pellini on Comprehensive Genomic Profiling and Repeat Biomarker Testing in NSCLC
Dr Pellini on Comprehensive Genomic Profiling and Repeat Biomarker Testing in NSCLC
Key Elements of an NGS Testing Report
Key Elements of an NGS Testing Report
Interpreting the Results of an NGS Testing Report
Interpreting the Results of an NGS Testing Report
How is Biomarker Testing Performed and Utilized?
How is Biomarker Testing Performed and Utilized?
Addressing Concerns Regarding Biomarker Testing
Addressing Concerns Regarding Biomarker Testing
Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort
Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort
Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS
Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS
Real-World Testing and Treatment Patterns Among Patients With Stage IV NSCLC: A Retrospective Observational Study
Real-World Testing and Treatment Patterns Among Patients With Stage IV NSCLC: A Retrospective Observational Study
Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results From the MYLUNG Pragmatic Study
Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results From the MYLUNG Pragmatic Study
What is NGS Testing?
What is NGS Testing?
What is DNA and RNA Testing in Biomarker Testing?
What is DNA and RNA Testing in Biomarker Testing?
Why Are You Choosing a Certain Testing Platform in Biomarker Testing?
Why Are You Choosing a Certain Testing Platform in Biomarker Testing?
How Do You Explain Adjuvant Therapy in NSCLC?
How Do You Explain Adjuvant Therapy in NSCLC?
When Should Patients With NSCLC be Referred to Thoracic Surgeons in Specialized Centers of Care?
When Should Patients With NSCLC be Referred to Thoracic Surgeons in Specialized Centers of Care?
What are the Benefits and Side Effects of TKIs?
What are the Benefits and Side Effects of TKIs?
What is a Biomarker in the Context of Tumors?
What is a Biomarker in the Context of Tumors?
What is a Gene Mutation and a Gene Fusion?
What is a Gene Mutation and a Gene Fusion?
What is a Chromosomal Rearrangement?
What is a Chromosomal Rearrangement?
How Do You Explain Neoadjuvant Therapy in NSCLC?
How Do You Explain Neoadjuvant Therapy in NSCLC?
What are Challenges Around Access to Testing?
What are Challenges Around Access to Testing?
What are the Benefits and Side Effects of Immunotherapy?
What are the Benefits and Side Effects of Immunotherapy?

All Oncology News